[Metabolic and renal changes in lymphoproliferative syndromes of childhood].
Authors report five patients with lymphoproliferative diseases who suffered from metabolic and renal disorders hyperuricemia, hyperphosforemia, hyperkaliemia, hypocalcemia and azotemia) during initial phase of chemotherapy. They comment on measures to prevent these disorders and the need of hemodialysis in some cases.
D058186:Acute Kidney Injury / Q000139:chemically induced; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002648:Child; D003520:Cyclophosphamide / Q000009:adverse effects; D005260:Female; D006801:Humans; D006934:Hypercalcemia / Q000139:chemically induced; D006947:Hyperkalemia / Q000139:chemically induced; D006996:Hypocalcemia / Q000139:chemically induced; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D010758:Phosphorus / Q000097:blood; D014527:Uric Acid / Q000097:blood
D000970:Antineoplastic Agents; D014527:Uric Acid; D010758:Phosphorus; D003520:Cyclophosphamide
Alteraciones metabólicas y renales en los síndromes linfoproliferativos de la infancia.